Voyager Therapeutics (VYGR) Net Cash Flow (2014 - 2026)

Voyager Therapeutics (VYGR) has 13 years of Net Cash Flow data on file, last reported at -$22.0 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 748.94% year-over-year to -$22.0 million; the trailing twelve-month figure through Mar 2026 stood at -$31.6 million (up 53.78% YoY), and the FY2025 full-year result was -$6.2 million, down 261.34% from the prior year.
• Net Cash Flow slipped to -$22.0 million in Q1 2026, from $17.3 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $169.4 million in Q1 2023 to a low of -$179.0 million in Q3 2023.
• A 5-year average of -$4.3 million and a median of $3.4 million in 2025 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow sank 119673.33% in 2022 and surged 1072.87% in 2023, its largest moves.
• Tracing VYGR's Net Cash Flow over 5 years: stood at $2.1 million in 2022, then surged by 68.32% to $3.5 million in 2023, then slumped by 1264.96% to -$41.2 million in 2024, then surged by 142.03% to $17.3 million in 2025, then slumped by 227.11% to -$22.0 million in 2026.
• Business Quant data shows VYGR's Net Cash Flow at -$22.0 million in Q1 2026, $17.3 million in Q4 2025, and $3.9 million in Q3 2025.